Follow-up: Follow-up grafted patients as long as their condition allows
Study summary
Long-term follow-up of Huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness. Indeed, some patients are likely to develop adverse effects and the impact of alloimmunisation phenomena remains to be explored.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult patients transplanted under the MIG-HD protocol
* Information and informed consent from patients or their representative
* Affiliation with a social security scheme or beneficiary
Exclusion Criteria:
* Patient under AME
* Patient unable to express consent and not subject to legal protection
* Knowned pregnancy or breastfeeding woman
Primary outcome measure(s)
Progression of the Unified Huntington's Disease Rating Scale (UHDRS) motor score — From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed For each patient
Progression of the Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP) motor score — From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed For each patient
Trial sites (1)
Facility
City
Region
Status
Assistance Publique Hôpitaux de Paris - Hôpital Henri Mondor
Créteil
France
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
